Bristol-Myers Squibb Company (BMY) Stock Price, Quote & News

Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unres...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 609 252 4621

Website: www.bms.com

Address:

Route 206 & Province Line Road, Princeton, United States

DonVigo May. 16 at 7:30 PM

$SLS $ABBV $BMY $MRK 40 billion? You must be brain dead. Is SLS peddling a cure for cancer or a treatment? Outrageous ...!

0 · Reply

DonVigo May. 16 at 7:22 PM

$SLS $ABBV $BMY $MRK That PR event may occur under the name of a different Company. Prove me wrong! Am not new to bios. And I said "may"

0 · Reply

55X_ROI_Q1_2026 May. 16 at 7:17 PM

$SLS Does Everyone Realize Aza+VEN, BAT for Control Arm Patients, Recently FAILED 3 Large Phase 3 trials? Including Failing the VIALE-M Trial for CR1/ First Remission Maintenance. It is not complicated. GPS is worth a Full $40B + to Big Pharma. A revolutionary, AML Remission Maintenance Immunotherapy, that extends Survival 3X 4X+ with low to No Side Effects, and an Unlimited dosing regime. Gps will Set Records for Patient Uptake rates. FDA/EU Orphan / Fast Track / Rare Priority Review - BLA NOW BEING Prepared. IP Rights Into 2037 - $ABBV $BMY $MRK all Know Gps is the only reason we are seeing Miraculous all Pooled Surivival. BAT/ AZA+VEN RECENTLY FAILED 3 Large Phase 3 Trials for AML Remission Maintenance. it is Not complicated.

0 · Reply

nakedshortspoopmarket May. 16 at 11:57 AM

$BMY $MRK $REGN $IOVA time to buy Iovance

0 · Reply

StocktwitsNews May. 16 at 1:26 AM

Regeneron’s Drug Combo Fails To Prove Superiority Over Merck’s Keytruda In Melanoma $REGN $VTI $VOO $MRK $BMY https://stocktwits.com/news/equity/markets/regeneron-drug-combo-fails-to-prove-superiority-over-merck-keytruda-in-melanoma/cZXVn8tRek0

0 · Reply

LiveSquawk May. 15 at 3:07 PM

$BMY | Bristol Myers Squibb Turns To China To Develop New Drugs In Newest Cross-Continent Collaboration – CNBC https://www.cnbc.com/2026/05/15/bristol-myers-squibb-turns-to-chinas-hengrui-to-replenish-pipeline.html

0 · Reply

taxplanr May. 15 at 2:20 PM

Cancer Free in 7 months with Ivermectin and Mebendazole $BNTX $MRNA $MRK $BMY https://makisw.substack.com/p/ivermectin-and-mebendazole-testimonial-a8d?utm_source=post-email-title&publication_id=1385328&post_id=197808872&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email

0 · Reply

javarich May. 15 at 12:59 PM

$ASST $BMNR $BMY $OPEN $PEP breaking news Hedgefollow just went down on Mike Alfred but didn't finish

0 · Reply

HedgeFollow May. 15 at 12:53 PM

🔍 𝗡𝗘𝗪 13F 𝗥𝗘𝗟𝗘𝗔𝗦𝗘𝗗 🔎 Rising star Fund Manager Mike Alfred just filed his 13F. Most Notable Trades: 𝗡𝗲𝘄 𝗟𝗔𝗥𝗚𝗘 Buys: $OPEN, $BMNR 𝗛𝗲𝗮𝘃𝗶𝗹𝘆 Boosted: $ASST 𝗥𝗲𝗱𝘂𝗰𝗲𝗱 by 84%: $PEP 𝗦𝗢𝗟𝗗 out: $BMY Source: hedgefollow.com/funds/Alpine+Fox+Capital+LLC

0 · Reply

ChipDistribution7 May. 14 at 9:02 PM

$TEM down 18% for me, but I’m still adding here. Feels like price action is lagging the thesis. AI in healthcare is still early, and Tempus sits right in the middle: oncology data + multimodal AI + clinical decision tools. Two recent catalysts matter: • Expanded $BMY collaboration using Tempus AI for trial design + patient selection • Medicare reimbursement approval for NeXT Personal MRD test (big commercialization unlock) Reimbursement is the real switch — it turns usage into scalable revenue and potentially unlocks a bigger sales cycle. With ~500PB of real-world clinical data, the moat is hard to replicate if execution stays intact. Down in price, but not in conviction yet. Follow me 👉@ChipDistribution7 for real-time updates and everything. Let’s make moves!

0 · Reply

Bristol Myers Squibb turns to China to develop new drugs in newest cross-continent collaboration

May 14, 2026, 11:40 AM EDT - 2 days ago

Bristol-Myers Squibb Company Transcript: Bank of America Global Healthcare Conference 2026

2026-05-14T15:30:17.000Z - 2 days ago

Tempus AI announces strategic collaboration with Bristol Myers

TEM

May 14, 2026, 8:30 AM EDT - 2 days ago

Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience

TEM

May 12, 2026, 4:01 PM EDT - 4 days ago

Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees

PCRX

May 12, 2026, 2:35 AM EDT - 5 days ago

Bristol-Myers Squibb and China's Hengrui Pharma Forge Tie-Up

May 12, 2026, 12:27 AM EDT - 5 days ago

Hengrui Pharma and Bristol Myers Squibb Announce Strategic Agreements to Advance Innovative Medicines Across Oncology, Hematology, and Immunology

May 12, 2026, 12:19 AM EDT - 5 days ago

China's Jiangsu Hengrui, Bristol Myers Squibb in deal worth up to $15.2 bln

2026-05-08T11:26:29.000Z - 8 days ago

Bristol Myers announces EU approved Sotyktu to treat PsA

May 8, 2026, 6:59 AM EDT - 8 days ago

Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults

2026-05-08T10:29:11.000Z - 8 days ago

Bristol Myers using AI to boost drug production volume, NY Times reports

May 6, 2026, 6:59 AM EDT - 10 days ago

Bristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026

May 5, 2026, 10:00 AM EDT - 11 days ago

Bristol-Myers Squibb Company Transcript: AGM 2026

May 4, 2026, 6:59 AM EDT - 12 days ago

Bristol Myers Squibb Launches “Won't Lose” Media Campaign Ahead of FIFA World Cup 2026™

May 1, 2026, 10:03 AM EDT - 15 days ago

Big Pharma M&A set for mega year as patent expiries drive deal urgency

ABBV GILD GSK LLY

2026-05-01T10:16:42.000Z - 15 days ago

Bristol Myers price target raised to $66 from $64 at Citi

Apr 30, 2026, 8:00 AM EDT - 16 days ago

Bristol-Myers Squibb Company Earnings Call Transcript: Q1 2026

Apr 30, 2026, 7:11 AM EDT - 16 days ago

Bristol Myers Squibb Logs Higher Sales, Profit

2026-04-30T11:05:31.000Z - 16 days ago

Options Volatility and Implied Earnings Moves Today, April 30, 2026

AAPL CAT LLY MA MO MRK RIVN

Apr 30, 2026, 7:01 AM EDT - 16 days ago

Bristol Myers posts higher-than-expected quarterly profit on blood thinner, cancer sales

Apr 30, 2026, 6:59 AM EDT - 16 days ago

Bristol Myers Squibb Reports First Quarter Financial Results for 2026

2026-04-29T18:35:58.000Z - 17 days ago

Notable companies reporting before tomorrow’s open

CAH CAT CHKP CI COP CROX FTV

Apr 24, 2026, 8:36 AM EDT - 22 days ago

Bristol Myers, Pfizer to offer blockbuster blood thinner through Mark Cuban's online pharmacy

PFE

2026-04-24T11:07:14.000Z - 22 days ago

Bristol Myers-Pfizer Alliance launch collaboration with Mark Cuban for Eliquis

PFE

Apr 24, 2026, 6:59 AM EDT - 22 days ago

Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company

2026-04-23T12:11:08.000Z - 23 days ago

Atrium Therapeutics earns $15M development milestone payment from Bristol Myers

RNA

Apr 23, 2026, 8:00 AM EDT - 23 days ago

Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

RNA

2026-04-21T12:11:47.000Z - 25 days ago

Foundation Medicine expands collaboration with Bristol Myers

Apr 21, 2026, 7:00 AM EDT - 25 days ago

Foundation Medicine Expands Existing Collaboration with Bristol Myers Squibb to Develop a Next-Generation Sequencing Companion Diagnostic to Identify Patients with Homozygous MTAP Deletion

Apr 20, 2026, 8:00 AM EDT - 26 days ago

Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer

ARDX

Apr 15, 2026, 7:00 AM EDT - 4 weeks ago

Beeline Medicines Debuts to Deliver Category-Leading Precision Therapies for People Living with Autoimmune and Inflammatory Diseases

Apr 9, 2026, 7:00 AM EDT - 5 weeks ago

Oxford BioTherapeutics Enters Strategic Collaboration with Bristol Myers Squibb to Discover and Develop Next-Generation T-cell Engagers for Solid Tumours

Apr 7, 2026, 2:54 PM EDT - 5 weeks ago

15 stocks to put on your list to buy when the market recovers

ADBE BK CVS KNSL MS NVDA TGT

Apr 3, 2026, 11:08 AM EDT - 6 weeks ago

Swiss industry body says US tariffs on pharmaceuticals will harm patients

ABBV AMGN AZN MRK NVO

Apr 2, 2026, 5:34 PM EDT - 6 weeks ago

Trump Administration Unveils Up to 100% Tariff on Branded Drugs

AZN NVO ABBV AMGN MRK

Apr 2, 2026, 5:33 PM EDT - 6 weeks ago

Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices

ABBV AMGN AZN MRK NVO

Apr 2, 2026, 3:29 PM EDT - 6 weeks ago

Drugmakers face 100% tariff unless they cut prices or produce drugs in US

AZN NVO ABBV AMGN MRK

Apr 2, 2026, 2:59 PM EDT - 6 weeks ago

Global pharma companies that have publicly announced Trump drug pricing agreements

ABBV AMGN AZN MRK

Mar 31, 2026, 6:59 AM EDT - 6 weeks ago

Bristol Myers Squibb Evolves and Expands Standing in the Gaap to Advance More Equitable Care in Multiple Myeloma as Program Marks Ten Years

Mar 29, 2026, 11:45 AM EDT - 6 weeks ago

Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Mar 28, 2026, 7:00 AM EDT - 7 weeks ago

Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)

Mar 23, 2026, 6:59 AM EDT - 7 weeks ago

Bristol Myers Squibb Reinforces Leadership in oHCM with New Camzyos (mavacamten) Data at American College of Cardiology Annual Scientific Session & Expo 2026 (ACC.26)

Mar 20, 2026, 4:42 PM EDT - 2 months ago

Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)

Mar 20, 2026, 12:23 PM EDT - 2 months ago

US FDA approves Bristol Myers Squibb's cancer drug for Hodgkin's lymphoma

Mar 19, 2026, 6:59 AM EDT - 2 months ago

Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026

Mar 18, 2026, 2:23 PM EDT - 2 months ago

TrumpRx lists many medicines at prices higher than paid in UK

ABBV AMGN AZN GILD GSK JNJ LLY

$Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma$

Mar 9, 2026, 6:59 AM EDT - 2 months ago

Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma

Mar 6, 2026, 9:59 PM EST - 2 months ago

U.S. FDA Approves Bristol Myers Squibb's Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis

Mar 2, 2026, 4:16 PM EST - 2 months ago

Bristol Myers Squibb Announces Dividend

Mar 2, 2026, 9:50 AM EST - 2 months ago

Bristol-Myers Squibb Company Transcript: TD Cowen 46th Annual Health Care Conference

Feb 26, 2026, 6:59 AM EST - 2 months ago

SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

Feb 25, 2026, 8:55 AM EST - 2 months ago

NYSE Content Update: Two MSCI Indexes to Begin Trading on NYSE Arca Options

Feb 23, 2026, 4:16 PM EST - 2 months ago

Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference

Feb 23, 2026, 6:59 AM EST - 2 months ago

Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia

$U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma$

Feb 17, 2026, 6:59 AM EST - 3 months ago

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma

Feb 12, 2026, 8:05 AM EST - 3 months ago

These 32 favorite stocks signal the bull market is running on fumes

AAPL ABT ADBE AMGN AVGO BAC BK

Feb 9, 2026, 1:00 AM EST - 3 months ago

Evinova and Bristol Myers Squibb Forge Strategic Collaboration to Optimize Clinical Development with Artificial Intelligence

Feb 5, 2026, 7:26 PM EST - 3 months ago

Bristol Myers Squibb CEO: Richest product pipeline we've had in the last decade

Feb 5, 2026, 8:00 AM EST - 3 months ago

Bristol-Myers Squibb Company Earnings Call Transcript: Q4 2025

Feb 5, 2026, 7:17 AM EST - 3 months ago

Bristol Myers Stock Rises. Why Fourth-Quarter Earnings Are Exciting Investors.

Feb 5, 2026, 7:09 AM EST - 3 months ago

Bristol Myers Squibb Revenue Ticks Up on Immuno-Oncology Growth

Feb 5, 2026, 7:01 AM EST - 3 months ago

Bristol Myers forecasts upbeat 2026, expecting Eliquis price cut to pay off

Feb 5, 2026, 6:59 AM EST - 3 months ago

Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025

Feb 4, 2026, 7:00 AM EST - 3 months ago

OXB Signs New Multi-Year Commercial Supply Agreement with Bristol Myers Squibb

DonVigo May. 16 at 7:30 PM

$SLS $ABBV $BMY $MRK 40 billion? You must be brain dead. Is SLS peddling a cure for cancer or a treatment? Outrageous ...!

0 · Reply

DonVigo May. 16 at 7:22 PM

$SLS $ABBV $BMY $MRK That PR event may occur under the name of a different Company. Prove me wrong! Am not new to bios. And I said "may"

0 · Reply

55X_ROI_Q1_2026 May. 16 at 7:17 PM

0 · Reply

nakedshortspoopmarket May. 16 at 11:57 AM

$BMY $MRK $REGN $IOVA time to buy Iovance

0 · Reply

StocktwitsNews May. 16 at 1:26 AM

0 · Reply

LiveSquawk May. 15 at 3:07 PM

0 · Reply

taxplanr May. 15 at 2:20 PM

0 · Reply

javarich May. 15 at 12:59 PM

$ASST $BMNR $BMY $OPEN $PEP breaking news Hedgefollow just went down on Mike Alfred but didn't finish

0 · Reply

HedgeFollow May. 15 at 12:53 PM

0 · Reply

ChipDistribution7 May. 14 at 9:02 PM

0 · Reply

trenddetector May. 14 at 3:25 PM

$BMY Opdivo (nivolumab) changed the game for cancer patients a decade ago and it's still going strong. Like Keytruda, it's a checkpoint inhibitor — but it takes a slightly different approach, blocking PD-1 on T cells to let the immune system do its job. Approved for melanoma, lung, kidney, and several other cancers. Opdivo is featured on YourCancerPath.com — a free platform helping patients navigate 22 cancer types with clear, no-jargon info. 🔗 YourCancerPath.com #Opdivo #cancer #BMY

0 · Reply

EVZ May. 14 at 2:22 PM

$BMY Market flying and this POS is still below 57!

0 · Reply

cloudhedge May. 14 at 1:52 PM

$TEM and $BMY are expanding their AI-driven clinical trial collaboration across five initial oncology and neuroscience programs. The partnership leverages Tempus Lens, multimodal real-world data, and AI analytics to improve patient segmentation and increase clinical trial success rates. Follow me 👉 @cloudhedge for real-time updates and everything. Let’s make moves!

0 · Reply

focafoca99 May. 14 at 1:33 PM

$BMY teamed with Tempus AI to boost AI-driven trial design and improve success odds in oncology and neuroscience. https://www.rapidticker.com/news/bmy-tempus-expands-strategic-collaboration-with-280ad9

0 · Reply

CHItraders May. 14 at 12:40 PM

TEM TEAMS WITH BMY TO AI-POWER CLINICAL TRIALS $TEM partners with $BMY to deploy AI, multimodal real-world data, and data science techniques to optimize clinical trial designs and lift success rates across five initial programs. 🔹 Targets higher Probability of Technical & Regulatory Success (PTRS). 🔹 Tempus brings the AI + real-world data firepower. 🔹 Precision medicine collab heating up.

1 · Reply

DefenseMania May. 14 at 12:22 AM

$AZN $BMY $EXEL $MRK

0 · Reply

NVDAMillionaire May. 13 at 10:56 PM

$BMY Excellent article that nails exactly where BMY stands right now. So if you want to update your BMY knowledge or get acquainted with BMY, this is a must read. https://everyticker.com/quote/BMY/analysis/bristol-myers-squibb-the-patent-cliff-is-priced-in-but-the-growth-portfolio-rerating-isn-t-nyse-bmy

0 · Reply

55X_ROI_Q1_2026 May. 13 at 1:10 PM

$SLS should be +100% today - and that is just a starter. GPS is worth a Full $40B + to Big Pharma. A revolutionary, AML Remission Maintenance Immunotherapy, that extends Survival 3X 4X+ with low to No Side Effects, and an Unlimited dosing regime. Gps will Set Records for Patient Uptake rates. FDA/EU Orphan / Fast Track / Rare Priority Review - BLA NOW BEING Prepared. IP Rights Into 2037 - $ABBV $BMY $MRK all Know Gps is the only reason we are seeing Miraculous all Pooled Surivival. BAT/ AZA+VEN RECENTLY FAILED 3 Large Phase 3 Trials for AML Remission Maintenance. it is Not complicated.

0 · Reply

55X_ROI_Q1_2026 May. 12 at 8:51 PM

$SLS @onthebalance How many repositioners just Got Left Off the Boat?? LOL GPS is worth a Full $40B + to Big Pharma. A revolutionary, AML Remission Maintenance Immunotherapy, that extends Survival 3X 4X+ with low to No Side Effects, and an Unlimited dosing regime. Gps will Set Records for Patient Uptake rates. FDA/EU Orphan / Fast Track / Rare Priority Review - BLA NOW BEING Prepared. IP Rights Into 2037 - $ABBV $BMY $MRK all Know Gps is the only reason we are seeing Miraculous all Pooled Surivival. BAT/ AZA+VEN RECENTLY FAILED 3 Large Phase 3 Trials for AML Remission Maintenance. it is Not complicated.

0 · Reply

SpudZone May. 12 at 3:07 PM

$BMY nice levels down here if looking for some safety, 5% dividend yield. Recent Analyst PTs over $70.

0 · Reply

taxplanr May. 12 at 1:39 PM

Study shows Fenbendazole shrinks breast cancer tumors with minimal systemic toxicity $BNTX $MRNA $MRK $BMY https://pubmed.ncbi.nlm.nih.gov/40756987/

0 · Reply

JFais May. 12 at 1:30 PM

$XBI - $BMY following $GSK into massive collaboration with Hengrui Pharma... "Some analyses suggest China = a third of all pipeline projects worldwide!" Major changes needed at the FDA if US isn't going to fall completely behind 🚨

0 · Reply

Market Cap	116.40B
Revenue (ttm)	48.19B
Net Income (ttm)	7.05B
EPS (ttm)	N/A
PE Ratio	9.57
Forward PE	8.99
Profit Margin	14.64%
Debt to Equity Ratio	2.21

Volume	10,824,300
Avg Vol	11,363,446
Day's Range	N/A - N/A
Shares Out	2.04B
Stochastic %K	77%
Beta	0.26
Analysts	Sell
Price Target	$63.12